Crossmark

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma

Crossref DOI link: https://doi.org/10.1136/jitc-2021-002923

Published Online: 2021-07-20

Published Print: 2021-07

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Zirngibl, Felix https://orcid.org/0000-0003-1764-4841
Ivasko, Sara M

Grunewald, Laura

Klaus, Anika

Schwiebert, Silke

Ruf, Peter

Lindhofer, Horst

Astrahantseff, Kathy

Andersch, Lena

Schulte, Johannes H

Lode, Holger N

Eggert, Angelika

Anders, Kathleen

Hundsdoerfer, Patrick

Künkele, Annette
Funding

Funding for this research was provided by:

Stiftung Charité
License Information

License valid from 2021-07-19